More MS news articles for December 1998

Cornell Study Reveals Nerve Regeneration Possible For The First Time Ever With Jacobson Resonator

http://biz.yahoo.com/prnews/981221/fl_jacobso_1.html

SOURCE: Jacobson Resonance Enterprises Inc.

BOCA RATON, Fla., Dec. 21 /PRNewswire/ -- A recent study performed at Cornell University Medical College has demonstrated that exposure to magnetic fields can result in growth and regeneration of nerves, according to Jacobson Resonance Enterprises Inc. (OTC Bulletin Board: JRSE - news). Researchers, led by Dr. Brij Saxena, used the Jacobson Resonator unit in applying low-level magnetic fields to mice sciatic nerves in vitro, in conducting the experiment. They found that exposure to the unit's low-level magnetic fields triggered growth and regeneration of nerve sections in culture medium. They also found that those nerves that were not exposed to the magnetic fields experienced nerve degeneration.

"At the end of the year, we found that included in the new growth was the myelin sheath, a structure responsible for normal nerve conduction of impulses," said Dr. Saxena. These findings are especially important because the myelin sheath is the one part of the nerve that is commonly lost in neurological diseases like multiple sclerosis.

"The results of this study serve as a milestone from which to view the possibility to help millions of people suffering from neurological diseases," said Dr. Jerry Jacobson, inventor of the technology and one of the world's leading researchers in the field of magneto therapy. I've always believed that this technology could be used to regenerate nerve cells and this study brings us one step closer to our ultimate goal, which is the demonstration of clinical efficacy," he added.

Jacobson Resonance Enterprises, Inc., a leader in the emerging field of bio-electro-magnetic resonance, is conducting double-blind randomized clinical studies at four sites in seeking FDA approval in the U.S. The company has also applied for a Certificate of Conformance, commonly known as a CE-Mark, which will allow manufacturing and distribution of its proprietary bio- electromagnetic medical equipment in the European Common Market for treatment and amelioration of pain. The CE-Mark is the European equivalent to the FDA marketing approval in the U.S.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.